Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School
Mallinckrodt
Baxter
McKesson
Merck

Last Updated: August 8, 2022

Investigational Drug Information for QAW039


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the development status for investigational drug QAW039?

QAW039 is an investigational drug.

There have been 18 clinical trials for QAW039. The most recent clinical trial was a Phase 3 trial, which was initiated on December 3rd 2015.

The most common disease conditions in clinical trials are Asthma, Eosinophilia, and Lung Diseases. The leading clinical trial sponsors are Novartis Pharmaceuticals and [disabled in preview].

There are twenty-eight US patents protecting this investigational drug and three hundred and fourteen international patents.

Recent Clinical Trials for QAW039
TitleSponsorPhase
Mechanistic Study of Anti-inflammatory Effects of Fevipiprant in Patients With Eosinophilic Asthma.Novartis PharmaceuticalsPhase 2
A Proof-of-mechanism Study of Multiple, Oral Doses of Fevipiprant (QAW039) in COPD Patients With EosinophiliaNovartis PharmaceuticalsPhase 2
Pharmacokinetics, Safety and Tolerability of Fevipiprant Delivered Via a Once Daily Chewable Tablet in Children Aged 6 to < 12 Years With AsthmaNovartis PharmaceuticalsPhase 2

See all QAW039 clinical trials

Clinical Trial Summary for QAW039

Top disease conditions for QAW039
Top clinical trial sponsors for QAW039

See all QAW039 clinical trials

US Patents for QAW039

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
QAW039 See Plans and Pricing Controlled release dosage form TRIASTEK, INC. (Nanjing, CN) See Plans and Pricing
QAW039 See Plans and Pricing JAK inhibitors containing a 4-membered heterocyclic amide THERAVANCE BIOPHARMA R&D IP, LLC (South San Francisco, CA) See Plans and Pricing
QAW039 See Plans and Pricing Fused imidazo-piperidine JAK inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (South San Francisco, CA) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School
Mallinckrodt
Baxter
McKesson
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.